Clinical Trial Update: KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for KRT-232 in combination with TL-895 for myelofibrosis and KRT-232 for JAK inhibitor-intolerant MF, covering Phase 1 and Phase 2 studies…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-et Myelofibrosis
• Post-pv Myelofibrosis

Drugs mentioned

• KRT-232
• TL-895

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Myelofibrosis, Post-PV MF | Phase 1, Phase 2 | Status: UNKNOWN